Gene mutations are closely related to cancers and drug sensitivity and noninvasive liquid biopsy was used to detect mutations of ctDNA in plasma. In this study, we performed exon sequencing of 416 cancer-related genes for cancer primary tissue and plasma samples of 20 patients in 11 cancers and obtained the comprehensive mutation landscape. We found that liquid biopsy is reliable in place of tissue biopsy. And 31 potential unique mutation prognostic markers were screened in 7 cancer types. Moreover, the drug-mutation network (DMN) was constructed and 9 gene mutations (B-Mut-9) were confirmed that can be served as drug biomarkers in blood. Our study showed that the variation in ctDNA can be used as the biomarkers for cancer prognosis and drug efficacy prediction. This can provide a reference for clinical noninvasive testing.

中文翻译：

---

基于ctDNA突变的11种癌症的药物敏感性特征。

基因突变与癌症和药物敏感性密切相关，无创液体活检被用于检测血浆中ctDNA的突变。在这项研究中，我们对11种癌症中20例患者的癌原发组织和血浆样本的416种与癌症相关的基因进行了外显子测序，并获得了全面的突变图谱。我们发现液体活检可代替组织活检可靠。并在7种癌症类型中筛选了31种潜在的独特突变预后标志物。此外，构建了药物突变网络（DMN），并确认了9个基因突变（B-Mut-9）可作为血液中的药物生物标记。我们的研究表明，ctDNA的变异可以用作癌症预后和药物疗效预测的生物标志物。这可以为临床无创检测提供参考。